For the last decade, immune-based therapies highlighted by immune checkpoint inhibitors have been the primary breakthroughs in oncology drug discovery. While this is happening, a significant number of new tumor-targeted agents exploiting novel mechanisms have been discovered.
This webinar highlights key examples with a focus on discovery paths and pharmacology, and examines the potential for combination approaches with immuno-oncology agents.
Edgar (Eddie) Wood, PhD
Senior Research Director
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.